Alcami Announces Deal with New Investors
Madison Dearborn Partners will acquire a majority ownership position in CDMO Alcami.
Alcami Corporation announced in a June 1, 2018 press statement that Madison Dearborn Partners, LLC (MDP), a private equity firm based in Chicago, will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation.
The Durham, NC-based contract development and manufacturing firm has 10 locations worldwide and provides API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, drug product manufacturing, and packaging and stability services tailored to small and mid-size pharmaceutical and biotechnology companies.
The current Alcami's management team, led by Chief Executive Officer, President, and Chairman, Stephan Kutzer, will continue with the company. The company expects the transaction to be completed in the third quarter of 2018, pending customary closing conditions.
"The entire Alcami team is excited to further enhance and evolve the small to mid-size pharma growth engine. As we enter our next stage of progress as a leading global, clinically-focused and fully-integrated contract development and manufacturing organization, we are proud to partner with MDP to expand our talented employee base and further develop our capabilities," said Kutzer in the press release.
Source: Alcami
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
